Home diagnostics company Cue Health announced its received FDA de novo authorization for its at-home COVID-19 test, dubbed the Cue COVID-19 Molecular Test.
The Cue COVID-19 Molecular Test detects genetic material from the SARS-CoV-2 virus. It consists of a nasal swab, or Cue Sample Wand, and a Cue Cartridge Reader. After taking the test, adults with respiratory infection symptoms receive the...
Health tech company Detect announced Friday it had received emergency use authorization from the Food and Drug Administration for its at-home molecular COVID-19 test.
The Detect test uses an app to help users perform and interpret their results. The company said it's also working on an electronic travel pass system with a telehealth service so its offering can be used for travel and events.
“...
On-demand, in-home care company Sprinter Health raised $33 million in Series A funding.
The round was led by Andreessen Horowitz, with participation from investors including General Catalyst, Accel and Google Ventures. Angel investors include DoorDash cofounder and CEO Tony Xu and former Senator Bill Frist.
WHAT IT DOES
Sprinter sends nurses and phlebotomists to conduct blood draws, vitals checks...
Malaysian telemedicine provider DOC2US has recently introduced a diagnostic system that enables rapid COVID-19 testing at home.
WHAT IT DOES
The Rapid Test Kit Intelligent System (RTKis) empowers corporations and public agencies to test, record, manage and report COVID-19 cases.
According to a press statement, the solution features a government-approved antigen test kit that allows users to self...
Everlywell, a leader in the at-home diagnostic testing space, has acquired PWNHealth and its subsidiary Home Access Health to form a new parent company called Everly Health.
PWNHealth and Home Access Health both have self-collected lab test services, and by combining the companies, Everly Health will support more than 20 million people annually in all 50 U.S. states, Canada and Puerto Rico,...
Today there are still a lot of questions around getting the workforce back into the office, clinic or manufacturing site. Digital health company Truepill is looking to address this issue by teaming up with the Health Transformation Alliance to offer Truepill's new employer-focused suite of COVID-19-focused diagnostics and digital tools to the former's members.
Truepill's new program will...
The FDA has issued its first emergency use authorization for a COVID-19 molecular diagnostic test that does not require a prescription and can be used at home.
Developed by Cue Health, the Cue COVID-19 Test for Home and Over the Counter Use was first authorized for point-of-care use last June.
It uses a nasal swab sample collected from the lower nose to detect the presence of SARS-CoV-2 RNA, and...
Everlywell, a digital consumer platform for ordering and viewing lab tests from home, has closed an oversubscribed $175 million Series D funding round, the Austin, Texas-based company announced this morning.
The raise brought in a slew of new investors hailing from BlackRock, the Chernin Group, Foresite Capital, Greenspring Associates, Lux Capital, Morningside Ventures and Portfolia. It also saw...
UK-based independent technology and product development company, the Technology Partnership Plc (TTP), is seeking partnerships for CoTest, a new pooled screening technology for COVID-19.
The technology can be used in any location, to screen up to 40 people at once for the virus, with results available in 30 minutes.
WHY IT MATTERS
CoTest enables screening of large groups, such as school classes...
Yesterday afternoon, the U.S. FDA issued an Emergency Use Authorization (EUA) to a COVID-19 molecular diagnostic test that provides individuals with a result within 30 minutes, in the comfort of their home.
As opposed to currently available at-home testing products, which have patients self-collect a nasal swab sample and ship it for processing in a lab, the Lucira COVID-19 All-in-One Test Kit...
